Skip to main content

Table 2 Ongoing clinical trials with immune checkpoint blockade pembrolizumab and lenvatinib in solid tumors

From: Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report

NCT numberNumber of patientsCancer typeTrial phaseLine of therapyGene or protein detectionPrimary endpointsCurrent status
NCT0360935929Advanced Gastric Cancer2 /ORRrecruiting
NCT030068876Transitional Cell Carcinoma
Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
1b /1.AE 2.DLTactive, not recruiting
NCT02501096329Tumors involving non-small cell lung cancer, renal cell carcinoma, endometrial cancer, urothelial cancer, squamous cell carcinoma of the head and neck, or melanoma1b(LEN)/2(PEM)Salvage therapy/1.MTD (phase 1b)
2.ORR 3.DLT
recruiting
NCT03006926104Hepatocellular Carcinoma1b /1.AE 2.DLT 3.ORR 4.DOR by Mrecist and RECIST 1.1 based on IIR analysisrecruiting
NCT03797326180Advanced Solid Tumors
Triple Negative Breast Cancer
Ovarian Cancer
Gastric Cancer
Colorectal Cancer
Glioblastoma
Biliary Tract Cancers
2Salvage therapydMMR for Colorectal Cancer1.ORR 2.Percentage of AE 3.Percentage of Discontinue Study Treatmentnot yet recruiting
NCT03776136100Advanced Melanoma2 /ORRrecruiting
NCT03820986660Malignant Melanoma2(PEM)/3(LEN)first-line/1.PFS 2.OSnot yet recruiting
NCT0297399760Thyroid Gland Carcinoma2metastasis/1.CR rate 2.Confirmed response raterecruiting
NCT03829332620Non-small Cell Lung Cancer3first-linePD-L1 ≥ 1%1.PFS 2.OSnot yet recruiting
NCT03713593750Hepatocellular Carcinoma3first-line/1.PFS 2.OSrecruiting
NCT03517449780Endometrial Neoplasms3 MMR1.PFS 2.OSrecruiting
NCT0332163024GastroEsophageal Cancer2salvage therapycorrelative biomarker studies.1.ORR 2.OSrecruiting
NCT03829319726Nonsquamous Non-small Cell Lung Cancer3first-linePD-L1Part 1: DLT AE Part 2: PFS OSnot yet recruiting
NCT028118611050Renal Cell Carcinoma3first-line/PFSrecruiting
NCT03516981192Advanced Non-Small Cell Lung Cancer2 Gene expression profile and TMBORRrecruiting
\